Medico Interpharm Profile
Key Indicators
- Authorised Capital ₹ 7.00 Cr
- Paid Up Capital ₹ 1.42 Cr
- Company Age 43 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 9.60 M
- Revenue Growth -95.20%
- Profit Growth 1365.91%
- Net Worth -0.22%
- Total Assets -0.00%
About Medico Interpharm
Medico Interpharm Limited (MIL) is a Public Limited Indian Non-Government Company incorporated in India on 10 March 1981 and has a history of 43 years and ten months. Its registered office is in Vadodara, Gujarat, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 7.00 Cr and a paid-up capital of Rs 1.42 Cr.
The company currently has active open charges totaling ₹9.60 M.
Suryakumar Bulusu, Uttambhai Patel, and Vadilal Khokhra serve as directors at the Company.
Company Details
-
Location
Vadodara, Gujarat, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24230GJ1981PLC004178
-
Company No.
004178
-
Company Classification
Public Limited Indian Non-Government Company
-
Incorporation Date
10 Mar 1981
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Medico Interpharm?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Suryakumar Bulusu
|
Director | 05-Aug-1997 | Current |
|
Uttambhai Patel
|
Director | 30-Apr-2005 | Current |
|
Vadilal Khokhra
|
Director | 14-Dec-2021 | Current |
Financial Performance of Medico Interpharm.
Medico Interpharm Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 95.2% decrease. The company also saw a substantial improvement in profitability, with a 1365.91% increase in profit. The company's net worth dipped by a decrease of 0.22%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Medico Interpharm?
In 2023, Medico Interpharm had a promoter holding of 55.83% and a public holding of 44.17%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0.96 Cr
₹0
Charges Breakdown by Lending Institutions
- State Bank Of India : 0.96 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 19 Aug 1994 | State Bank Of India | ₹7.70 M | Open |
| 19 Sep 1986 | State Bank Of India | ₹0.95 M | Open |
| 19 Sep 1986 | State Bank Of India | ₹0.95 M | Open |
How Many Employees Work at Medico Interpharm?
Unlock and access historical data on people associated with Medico Interpharm, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medico Interpharm, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medico Interpharm's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
